AMEX · MYO

Myomo Inc.

$1.00 +$0.03 (+3.09%) 1D Market open

Key Metrics

$37.48M
Market cap
82.25×
P/E · TTM
$281.47K
Revenue · TTM
$455.66K
Net income
EPS · TTM $0.01
Dividend yield
Free cash flow
Beta · 1Y 1.67
EBITDA · TTM
Gross margin 103.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 20
    From its Jun 10 high, the share price fell 42%.

    Peak close $1.54 on Jun 10; trough close $0.90 on Jul 20. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -42%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 15
    The stock moved +17.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 15
  • Jun 10
    The stock moved +17.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$37.48M
Enterprise value$35.44M
Shares outstanding38.6M
52-wk range$0.61 – $2.06
Avg volume · 20D449.3K
Net cash $2.04M
Book value / share$0.22
IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies
ExchangeAMEX
About Myomo Inc.
IPO dateJun 12, 2017
Employees195

Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E82.25
P/S133.15
P/FCF
EV/EBITDA
EV/Sales125.92
Graham №$0.23

Profitability

Gross 103.7%
Operating 179.6%
Net 161.9%
FCF
ROE / ROIC 2.7% · —

Financial Health

Current ratio2.73
Quick ratio2.36
Debt / equity1.52
Debt / EBITDA
Net cash $2.04M
Working capital$16.27M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

-3.2
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$0.23 vs $1.06
Trades 4.6× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings